Post-earnings recap
Reported
Tue, May 3, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.44% following the earnings announcement, likely due to the lack of revenue data and absence of future guidance. Investors may be cautious as they await more information on the company's pipeline developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | +30.00% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting ongoing efforts to develop their product pipeline. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.